Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease

D.D. Sin; B.E. Miller; A. Duvoix; S.F. Man; X. Zhang; E.K. Silverman; J.E. Connett; N.A. Anthonisen; R.A. Wise; D. Tashkin; B.R. Celli; L.D. Edwards; N. Locantore; W. MacNee; R. Tal-Singer; (incl. E. Wouters) ECLIPSE Investigators; D.A. Lomas

doi:10.1164/rccm.201008-1220OC

Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease

D.D. Sin^*, B.E. Miller, A. Duvoix, S.F. Man, X. Zhang, E.K. Silverman, J.E. Connett, N.A. Anthonisen, R.A. Wise, D. Tashkin, B.R. Celli, L.D. Edwards, N. Locantore, W. MacNee, R. Tal-Singer, (incl. E. Wouters) ECLIPSE Investigators, D.A. Lomas

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

RATIONALE: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. OBJECTIVES: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. MEASUREMENTS AND MAIN RESULTS: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. CONCLUSIONS: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.

Original language	English
Pages (from-to)	1187-1192
Number of pages	6
Journal	American Journal of Respiratory and Critical Care Medicine
Volume	183
Issue number	9
DOIs	https://doi.org/10.1164/rccm.201008-1220OC
Publication status	Published - 1 May 2011

Keywords

biomarker
chronic obstructive pulmonary disease
PARC/CCL-18
chemokine
CC-CHEMOKINE
T-CELLS
COPD
BIOMARKERS
MORTALITY
ECLIPSE
CCL18

Access to Document

10.1164/rccm.201008-1220OC

https://europepmc.org/articles/pmc3114051?pdf=renderLicence: Other

Cite this

Sin, D. D., Miller, B. E., Duvoix, A., Man, S. F., Zhang, X., Silverman, E. K., Connett, J. E., Anthonisen, N. A., Wise, R. A., Tashkin, D., Celli, B. R., Edwards, L. D., Locantore, N., MacNee, W., Tal-Singer, R., ECLIPSE Investigators, & Lomas, D. A. (2011). Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 183(9), 1187-1192. https://doi.org/10.1164/rccm.201008-1220OC

@article{9116e6eef0894ed48fc36b87bdc57314,

title = "Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease",

abstract = "RATIONALE: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. OBJECTIVES: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. MEASUREMENTS AND MAIN RESULTS: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. CONCLUSIONS: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.",

keywords = "biomarker, chronic obstructive pulmonary disease, PARC/CCL-18, chemokine, CC-CHEMOKINE, T-CELLS, COPD, BIOMARKERS, MORTALITY, ECLIPSE, CCL18",

author = "D.D. Sin and B.E. Miller and A. Duvoix and S.F. Man and X. Zhang and E.K. Silverman and J.E. Connett and N.A. Anthonisen and R.A. Wise and D. Tashkin and B.R. Celli and L.D. Edwards and N. Locantore and W. MacNee and R. Tal-Singer and {ECLIPSE Investigators}, {(incl. E. Wouters)} and D.A. Lomas",

year = "2011",

month = may,

day = "1",

doi = "10.1164/rccm.201008-1220OC",

language = "English",

volume = "183",

pages = "1187--1192",

journal = "American Journal of Respiratory and Critical Care Medicine",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "9",

}

Sin, DD, Miller, BE, Duvoix, A, Man, SF, Zhang, X, Silverman, EK, Connett, JE, Anthonisen, NA, Wise, RA, Tashkin, D, Celli, BR, Edwards, LD, Locantore, N, MacNee, W, Tal-Singer, R, ECLIPSE Investigators & Lomas, DA 2011, 'Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 9, pp. 1187-1192. https://doi.org/10.1164/rccm.201008-1220OC

TY - JOUR

T1 - Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease

AU - Sin, D.D.

AU - Miller, B.E.

AU - Duvoix, A.

AU - Man, S.F.

AU - Zhang, X.

AU - Silverman, E.K.

AU - Connett, J.E.

AU - Anthonisen, N.A.

AU - Wise, R.A.

AU - Tashkin, D.

AU - Celli, B.R.

AU - Edwards, L.D.

AU - Locantore, N.

AU - MacNee, W.

AU - Tal-Singer, R.

AU - ECLIPSE Investigators, (incl. E. Wouters)

AU - Lomas, D.A.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - RATIONALE: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. OBJECTIVES: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. MEASUREMENTS AND MAIN RESULTS: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. CONCLUSIONS: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.

AB - RATIONALE: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. OBJECTIVES: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. MEASUREMENTS AND MAIN RESULTS: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. CONCLUSIONS: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.

KW - biomarker

KW - chronic obstructive pulmonary disease

KW - PARC/CCL-18

KW - chemokine

KW - CC-CHEMOKINE

KW - T-CELLS

KW - COPD

KW - BIOMARKERS

KW - MORTALITY

KW - ECLIPSE

KW - CCL18

U2 - 10.1164/rccm.201008-1220OC

DO - 10.1164/rccm.201008-1220OC

M3 - Article

C2 - 21216880

SN - 1073-449X

VL - 183

SP - 1187

EP - 1192

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

IS - 9

ER -

Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this